Health TrialsbyHealthPanel

CYP1A2 and ADORA2A Genotypes and Endurance Performance.

ConditionHealthy
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-35
SponsorMasaryk University

About this trial

The aim of this randomized, double-blind, placebo-controlled experiment will be to assess the potential effect of the selected gene polymorphism (CYP1A2, ADORA2A) on performance after caffeine ingestion.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

healthy person

any training status

within age limits

without contraindications to perform the test on a bicycle trainer

Disqualifiers

Pregnancy

Breast feeding

Cardiovascular disease

Hypertension

Trial design

Design model

Crossover

Treatments tested in this trial

  • Caffeine 2 mg

    Dietary supplement

    To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects.

  • Caffeine 4 mg

    Dietary supplement

    To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects.

  • Caffeine 0 mg

    Dietary supplement

    To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects.

Treatment groups

60 Participants
are divided into 3 treatment groups
Group A: Caffeine 2 mgActive comparator 1 intervention
Group B: Caffeine 4 mgActive comparator 1 intervention
Group C: PlaceboPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

Efficacy of caffeine to improve endurance performance (time to complete 10 km trial)

To determine if caffeine intake improves endurance performance compared to placebo. Efficacy of caffeine doses (2 mg/kg and 4 mg/kg) to shorten the time needed to complete the 10 km time trial.

Time frame
2 Hours

Secondary outcomes

1

Caffeine ingestion and genotype interaction

To determine if different variants of selected genes affect the potential ergogenic effect of caffeine. A buccal mucosa smear will be taken to identify variants of CYP1A2 and ADORA2A genes to determine which genes/variants are associated with improvement in time trial performance after caffeine ingestion.

Time frame
1 day

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Masaryk University

Lead sponsor

Source ClinicalTrials.gov
Apply now